Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, will announce its interim results for the six months ended 31 March 2009 at 7.00am (BST) on Tuesday 19 May 2009.
Professor Mark Ferguson, CEO, and David Blain, CFO, will host a briefing for analysts at 09:30am (BST) on the day at the offices of Buchanan Communications, 45 Moorfields, London, EC2Y 9AE.
Printer-friendly version